Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Today's report puts a spotlight on the Health Care Sector, which is assuming a global leadership role vs. other Sectors. We also focus on the Communications Sector as we are seeing steady relative strength ranking (RSR) improvements over the last couple of months. At the Group level, we highlight select smid-cap Casinos &amp; Gaming stocks. Finally, India’s S&amp;P BSE SENSEX is breaking out to new all-time highs as RS bullishly inflects, we highlight actionable stocks.

Today's report puts a spotlight on the Health Care Sector, which is assuming a global leadership role vs. other Sectors. We also focus on the Communications Sector as we are seeing steady relative strength ranking (RSR) improvements over the last couple of months. At the Group level, we highlight select smid-cap Casinos &amp; Gaming stocks. Finally, India’s S&amp;P BSE SENSEX is breaking out to new all-time highs as RS bullishly inflects, we highlight actionable stocks.

Global Strategy: Health Care Outperforming - Overweight; India Breaking Out -Add Exposure

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

Although the Japanese drug industry suffers from a lack of scale, where it is good is in applying manufacturing techniques to develop not just potentially efficacious molecule, but a portfolio of them. This enables the company in question to develop drugs on its own or in partnership, but also to license out the system, as <a href="https://www.smartkarma.com/entities/13514" target="_blank" data-smartkarma-citation="entities:13514:1">Peptidream</a> does. Those companies that have this capability (be they large caps like <a href="https://www.smartkarma.com/entities/4489" target="_blank" data-smartkarma-citation="entities:4489:1">Chugai Pharmaceutical </a>with its recycling antibody technology or small caps like <a href="https://www.smartkarma.com/entities/17760" target="_blank" data-smartkarma-citation="entities:17760:1">Nanocarrier</a>…

Although the Japanese drug industry suffers from a lack of scale, where it is good is in applying manufacturing techniques to develop not just potentially efficacious molecule, but a portfolio of them. This enables the company in question to develop drugs on its own or in partnership, but also to license out the system, as Peptidream does. Those companies that have this capability (be they large caps like Chugai Pharmaceutical with its recycling antibody technology or small caps like Nanocarrier…

Medrx - Japan Biotech Microcap in Potential Big Licensing Deal

On the surface, <a href="https://www.smartkarma.com/entities/13514" target="_blank" data-smartkarma-citation="entities:13514:1">Peptidream's (4587 JP)</a> deal with <a href="https://www.smartkarma.com/entities/1132" target="_blank" data-smartkarma-citation="entities:1132:1">Johnson &amp; Johnson's (JNJ US)</a> Janssen unit looks no different from the deals they have cut with other firms, with the exception of the total milestone payments. Normally, this is undisclosed, but in this instance, it has been announced – it is US$1.15bil – possibly because it is too large a number to be kept from investors, which is why the shares soared on Monday.  The deal sees J&amp;J access Peptidream's peptide drug conjugate capabilities as well…

On the surface, Peptidream's (4587 JP) deal with Johnson &amp; Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with other firms, with the exception of the total milestone payments. Normally, this is undisclosed, but in this instance, it has been announced – it is US$1.15bil – possibly because it is too large a number to be kept from investors, which is why the shares soared on Monday.  The deal sees J&amp;J access Peptidream's peptide drug conjugate capabilities as well…

PeptiDream: J&J Latest Drug Major to Tie Up

<a href="https://www.smartkarma.com/entities/18055" target="_blank" data-smartkarma-citation="entities:18055:1">Kyowa Hakko Kirin's (4151 JP)</a> announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for Cutaneous T-cell Lymphoma (CTCL, a variation of NHL), is of greater long-term significance than it is in the short term. CTCL is a minor indication and ATL (adult T-cell leukemia/lymphoma) which moga is in Phase II for isn’t much bigger. However, while the CC chemokine receptor 4 (CCR4) targeted by mogamulizumab is primarily expressed on leukemic cells…

Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for Cutaneous T-cell Lymphoma (CTCL, a variation of NHL), is of greater long-term significance than it is in the short term. CTCL is a minor indication and ATL (adult T-cell leukemia/lymphoma) which moga is in Phase II for isn’t much bigger. However, while the CC chemokine receptor 4 (CCR4) targeted by mogamulizumab is primarily expressed on leukemic cells…

Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs

Thematic (Sector/Industry)

The suggestion of government orchestration against <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono</a>’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the Nikkei that the Japanese Health Ministry is considering setting rules on new drug usage during this fiscal year, starting with <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono</a>’s Opdivo and <a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091">Astellas</a>’s Repatha. Patients may be limited to those who can see certain impact from the treatment, which in turn would mean the drug could only be prescribed at those institutions with the facilities to check…

The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the Nikkei that the Japanese Health Ministry is considering setting rules on new drug usage during this fiscal year, starting with Ono’s Opdivo and Astellas’s Repatha. Patients may be limited to those who can see certain impact from the treatment, which in turn would mean the drug could only be prescribed at those institutions with the facilities to check…

Opdivo Singled Out in Government Rule Change

Japan

NanoCarrier Co., Ltd. is a biotech company that utilizes micellar nanoparticle (polymeric micelles) technology for the production and development of pharmaceuticals focusing mainly on cancer therapies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nanocarrier (4571 JP)

Global Strategy: Health Care Outperforming - Overweight; India Breaking Out -Add Exposure

Today's report puts a spotlight on the Health Care Sector, which is assuming a global leadership role vs. other Sectors. We also focus on...

Vermilion Research

Medrx - Japan Biotech Microcap in Potential Big Licensing Deal

Although the Japanese drug industry suffers from a lack of scale, where it is good is in applying manufacturing techniques to develop not just...

Pelham Smithers Associates

PeptiDream: J&J Latest Drug Major to Tie Up

On the surface, Peptidream's (4587 JP) deal with Johnson & Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with...

Pelham Smithers Associates

Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs

Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...

Pelham Smithers Associates

Opdivo Singled Out in Government Rule Change

The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...

Pelham Smithers Associates

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)